Scotiabank lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $74 from $75 and keeps an Outperform rating on the shares. The firm is impressed by the company’s regulatory and clinical execution in Q4, the analyst tells investors. Scotiabank believes Agios is well-equipped to accelerated growth of the Pyrukynd franchise and remains cautiously optimistic on mitapivat’s point of sickening.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals Reports Strong 2024 Financial Results
- Agios Pharmaceuticals Earnings Call Highlights Growth & Pipeline Progress
- Agios Pharma: Promising Growth with Strategic Market Expansion and Pipeline Advancements
- Agios Pharmaceuticals reports Q4 revenue $10.7M, consensus $9.35M
- Agios Pharmaceuticals reports results from Phase 3 ACTIVATE-Kids study
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue